Paul Cahalin

1.0k total citations
14 papers, 460 citations indexed

About

Paul Cahalin is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Molecular Biology. According to data from OpenAlex, Paul Cahalin has authored 14 papers receiving a total of 460 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hematology, 6 papers in Public Health, Environmental and Occupational Health and 5 papers in Molecular Biology. Recurrent topics in Paul Cahalin's work include Acute Myeloid Leukemia Research (12 papers), Acute Lymphoblastic Leukemia research (6 papers) and Multiple Myeloma Research and Treatments (5 papers). Paul Cahalin is often cited by papers focused on Acute Myeloid Leukemia Research (12 papers), Acute Lymphoblastic Leukemia research (6 papers) and Multiple Myeloma Research and Treatments (5 papers). Paul Cahalin collaborates with scholars based in United Kingdom, Denmark and Canada. Paul Cahalin's co-authors include Alan K. Burnett, Nigel H. Russell, Robert K. Hills, Richard E. Clark, Jonathan Kell, Lars Kjeldsen, Mike Dennis, Ian F. Thomas, Don Milligan and Lone Smidstrup Friis and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Lancet Oncology.

In The Last Decade

Paul Cahalin

14 papers receiving 454 citations

Peers

Countries citing papers authored by Paul Cahalin

Since Specialization

Citations

This map shows the geographic impact of Paul Cahalin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Cahalin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Cahalin more than expected).

Fields of papers citing papers by Paul Cahalin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Cahalin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Cahalin. The network helps show where Paul Cahalin may publish in the future.

Co-authorship network of co-authors of Paul Cahalin

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Cahalin. A scholar is included among the top collaborators of Paul Cahalin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Cahalin. Paul Cahalin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	MRD Directed Treatment Intensification with Either FLAG-Ida or DA-Cladribine Improves Survival in Older AML Patients: Results from the NCRI AML18 Randomised Trial 2023 ·Blood ·Nigel H. Russell, Abin Thomas, Robert K. Hills, Ian Thomas, Amanda Gilkes, (unknown), Sarah S. Burns, (unknown), Georgia Andrew, (unknown), Jenny Byrne, Rob S. Sellar, Richard Kelly, Paul Cahalin, Ulrik Malthe Overgaard, Priyanka Mehta, Mike Dennis, Steven Knapper, Sylvie Freeman	4
2	A randomised comparison of FLAG‐Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial 2022 ·British Journal of Haematology ·Nigel H. Russell, Robert K. Hills, Lars Kjeldsen, Richard E. Clark, Sahra Ali, Paul Cahalin, Ian F. Thomas, Alan K. Burnett	1
3	Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial 2018 ·Haematologica ·Alan K. Burnett, (unknown), Steven Knapper, Asim Khwaja, Marion Sweeney, Lars Kjeldsen, (unknown), (unknown), Paul Cahalin, Richard E. Clark, Robert K. Hills, Nigel H. Russell	13
4	A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial 2018 ·Leukemia ·Alan K. Burnett, Robert K. Hills, Olav Wendelboe Nielsen, Sylvie Freeman, Arwa Ali, Paul Cahalin, Ann Hunter, Ian F. Thomas, Nigel H. Russell	12
5	Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations 2018 ·Journal of Clinical Oncology ·Sylvie Freeman, Robert K. Hills, Paul Virgo, Naeem Khan, (unknown), Richard Dillon, Amanda Gilkes, (unknown), Ove Juul Nielsen, James D. Cavenagh, Gail Jones, Asim Khwaja, Paul Cahalin, Ian Thomas, David Grimwade, Alan K. Burnett, Nigel H. Russell	136
6	A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia 2016 ·Leukemia ·(unknown), Alan K. Burnett, Nigel H. Russell, Robert K. Hills, Jonathan Kell, Olav Wendelboe Nielsen, Mike Dennis, Paul Cahalin, Chris Pocock, Sahra Ali, Sarah S. Burns, Sylvie Freeman, D Milligan, Richard E. Clark	17
7	A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia 2015 ·Leukemia ·Alan K. Burnett, Nigel H. Russell, Robert K. Hills, Nicki Panoskaltsis, Asim Khwaja, Claire Hemmaway, Paul Cahalin, Richard E. Clark, D Milligan	30
8	A Comparison of 1 or 2 Courses of High Dose Cytarabine As Consolidation in Younger Patients with AML: First Results of the UK NCRI AML17 Trial 2015 ·Blood ·Nigel H. Russell, Robert K. Hills, Sylvie Freeman, Steven Knapper, Lars Kjeldsen, Ian Thomas, Jamie Cavenagh, Paul Cahalin, Mary Frances McMullin, Alan K. Burnett	1
9	A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients 2015 ·Blood ·Alan K. Burnett, Nigel H. Russell, Robert K. Hills, Jonathan Kell, Jamie Cavenagh, Lars Kjeldsen, Mary‐Frances McMullin, Paul Cahalin, Mike Dennis, Lone Smidstrup Friis, Ian F. Thomas, Don Milligan, Richard E. Clark	194
10	A Comparison of Limited Consolidation Chemotherapy Therapy Or Not, and Demethylation Maintenance Or Not in Older Patients with Aml and High Risk Mds: Long Term Results of the Uk Ncri Aml16 Trial 2015 ·Alan K. Burnett, Nicola S. Russell, (unknown), Lars Kjeldsen, D W Milligan, Christopher Pocock, Paul Cahalin, Jonathan Kell, Michael Dennis, Robert K. Hills	6
11	A Randomised Comparison of Daunorubicin 90mg/m2 Vs 60mg/m2 in AML Induction: Results from the UK NCRI AML17 Trial in 1206 Patients 2014 ·Blood ·Alan K. Burnett, Nigel H. Russell, Robert K. Hills, Jonathan Kell, Jamie Cavenagh, Lars Kjeldsen, Mary Frances McMullin, Paul Cahalin, Mike Dennis, Donald Milligan, Richard E. Clark	2
12	A tale of two tumours and a plea for progress 2012 ·The Lancet Oncology ·Rosalie Fisher, Paul Cahalin, Martin Gore, James Larkin	1
13	A Comparison of Daunorubicin/Ara-C (DA) Versus Daunorubicin/Clofarabine (DClo) and Two Versus Three Courses of Total Treatment for Older Patients with AML and High Risk MDS: Results of the UK NCRI AML16 Trial 2012 ·Blood ·Alan K. Burnett, Nigel H. Russell, Jonathan Kell, Lars Kjeldsen, Donald Milligan, Paul Cahalin, Robert K. Hills	8
14	The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome 2011 ·Leukemia ·Alan K. Burnett, Robert K. Hills, Ann Hunter, D Milligan, Jonathan Kell, Keith Wheatley, J. A. Liu Yin, (unknown), Paul Cahalin, J Craig, David Bowen, Nigel H. Russell	35

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact